Literature DB >> 17183024

Role of LCAT in HDL remodeling: investigation of LCAT deficiency states.

Bela F Asztalos1, Ernst J Schaefer, Katalin V Horvath, Shizuya Yamashita, Michael Miller, Guido Franceschini, Laura Calabresi.   

Abstract

To better understand the role of LCAT in HDL metabolism, we compared HDL subpopulations in subjects with homozygous (n = 11) and heterozygous (n = 11) LCAT deficiency with controls (n = 22). Distribution and concentrations of apolipoprotein A-I (apoA-I)-, apoA-II-, apoA-IV-, apoC-I-, apoC-III-, and apoE-containing HDL subpopulations were assessed. Compared with controls, homozygotes and heterozygotes had lower LCAT masses (-77% and -13%), and LCAT activities (-99% and -39%), respectively. In homozygotes, the majority of apoA-I was found in small, disc-shaped, poorly lipidated prebeta-1 and alpha-4 HDL particles, and some apoA-I was found in larger, lipid-poor, discoidal HDL particles with alpha-mobility. No apoC-I-containing HDL was noted, and all apoA-II and apoC-III was detected in lipid-poor, prebeta-mobility particles. ApoE-containing particles were more disperse than normal. ApoA-IV-containing particles were normal. Heterozygotes had profiles similar to controls, except that apoC-III was found only in small HDL with prebeta-mobility. Our data are consistent with the concepts that LCAT activity: 1) is essential for developing large, spherical, apoA-I-containing HDL and for the formation of normal-sized apoC-I and apoC-III HDL; and 2) has little affect on the conversion of prebeta-1 into alpha-4 HDL, only slight effects on apoE HDL, and no effect on apoA-IV HDL particles.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17183024     DOI: 10.1194/jlr.M600403-JLR200

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  62 in total

1.  Speciated human high-density lipoprotein protein proximity profiles.

Authors:  Kekulawalage Gauthamadasa; Corina Rosales; Henry J Pownall; Stephen Macha; W Gray Jerome; Rong Huang; R A Gangani D Silva
Journal:  Biochemistry       Date:  2010-11-23       Impact factor: 3.162

2.  Apolipoproteins A-I, A-II and E are independently distributed among intracellular and newly secreted HDL of human hepatoma cells.

Authors:  Baiba K Gillard; Hu-Yu Alice Lin; John B Massey; Henry J Pownall
Journal:  Biochim Biophys Acta       Date:  2009-07-25

Review 3.  Three-dimensional models of HDL apoA-I: implications for its assembly and function.

Authors:  Michael J Thomas; Shaila Bhat; Mary G Sorci-Thomas
Journal:  J Lipid Res       Date:  2008-05-30       Impact factor: 5.922

Review 4.  Therapeutic interventions to enhance apolipoprotein A-I-mediated cardioprotection.

Authors:  Michael J Haas; Arshag D Mooradian
Journal:  Drugs       Date:  2010-05-07       Impact factor: 9.546

5.  Complexities of plasma apolipoprotein C-III metabolism.

Authors:  Frank M Sacks; Chunyu Zheng; Jeffrey S Cohn
Journal:  J Lipid Res       Date:  2011-03-18       Impact factor: 5.922

6.  Short communication: effects of omega-3 fatty acids on triglycerides and high-density lipoprotein subprofiles in HIV-infected persons with hypertriglyceridemia.

Authors:  Anu Paranandi; Bela F Asztalos; Alexandra Mangili; Jefferey Kuvin; Jul Gerrior; Heidi Sheehan; Sally C Skinner; Alice M Tang; Christine A Wanke
Journal:  AIDS Res Hum Retroviruses       Date:  2014-08       Impact factor: 2.205

7.  Mass spectrometric determination of apolipoprotein molecular stoichiometry in reconstituted high density lipoprotein particles.

Authors:  John B Massey; Henry J Pownall; Stephen Macha; Jamie Morris; Matthew R Tubb; R A Gangani D Silva
Journal:  J Lipid Res       Date:  2009-01-28       Impact factor: 5.922

8.  High-density lipoprotein subpopulation profiles in lipoprotein lipase and hepatic lipase deficiency.

Authors:  Mariko Tani; Katalin V Horvath; Benoit Lamarche; Patrick Couture; John R Burnett; Ernst J Schaefer; Bela F Asztalos
Journal:  Atherosclerosis       Date:  2016-08-20       Impact factor: 5.162

9.  Selective delipidation of plasma HDL enhances reverse cholesterol transport in vivo.

Authors:  Frank M Sacks; Lawrence L Rudel; Adam Conner; Hassibullah Akeefe; Gerhard Kostner; Talal Baki; George Rothblat; Margarita de la Llera-Moya; Bela Asztalos; Timothy Perlman; Chunyu Zheng; Petar Alaupovic; Jo-Ann B Maltais; H Bryan Brewer
Journal:  J Lipid Res       Date:  2009-01-14       Impact factor: 5.922

10.  Potent and selective PPAR-alpha agonist LY518674 upregulates both ApoA-I production and catabolism in human subjects with the metabolic syndrome.

Authors:  John S Millar; Danielle Duffy; Ramprasad Gadi; LeAnne T Bloedon; Richard L Dunbar; Megan L Wolfe; Rajesh Movva; Ashish Shah; Ilia V Fuki; Mary McCoy; Cynthia J Harris; Ming-Dauh Wang; Daniel C Howey; Daniel J Rader
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-11-06       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.